KROS

Keros Therapeutics (KROS) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.

SEC Filings

Keros Therapeutics Doses First Patient In Mid-Stage Rinvatercept Trial For Duchenne Muscular Dystrophy

The clinical-stage biotech expects initial safety and efficacy data from the open-label DMD study in the first half of 2027.

SEC Filings

Takeda To Pay Keros Therapeutics $20 Million As Late-Stage Blood Disorder Trial Doses First Patient

Keros plans to pass 25% of the net proceeds to stockholders after the milestone triggers under its Takeda license agreement.